
This document updates and expands the initial zzso Diseases Society of America zzso zzso and zzso zzso that was published in 1997 and first updated in zzso It is intended as a guide for the use of zzso agents in managing patients with cancer who experience zzso fever and zzso Recent advances in zzso drug development and technology, clinical trial results, and extensive clinical experience have informed the approaches and recommendations zzso Because the previous iteration of this zzso in 2002, we have a developed a clearer definition of which populations of patients with cancer may benefit most from antibiotic, zzso and zzso zzso Furthermore, zzso zzso patients as being at high risk or low risk for infection according to presenting signs and symptoms, underlying cancer, type of therapy, and medical zzso has become essential to the treatment zzso zzso zzso is a recommended starting point for managing patients with fever and zzso In addition, earlier detection of invasive zzso infections has led to debate regarding optimal use of empirical or zzso zzso therapy, although zzso are still zzso What has not changed is the indication for immediate empirical zzso zzso It remains true that all patients who present with fever and zzso should be treated swiftly and broadly with antibiotics to treat both zzso and zzso zzso Finally, we note that all Panel members are from institutions in the United States or zzso thus, these guidelines were developed in the context of North American zzso Some recommendations may not be as zzso outside of North America, in areas where differences in available zzso in the zzso zzso and/or in health zzso economic conditions zzso Regardless of venue, clinical vigilance and immediate treatment are the universal keys to managing zzso patients with fever and/or zzso 

